Keros Therapeutics, Inc. (KROS)

In November 2025, Keros Therapeutics reported strong third-quarter earnings, but the stock declined due to institutional selling and mixed analyst sentiment. In December 2024, the stock plummeted after the company halted high-dose arms of its Phase 2 TROPOS trial due to safety concerns. In April 2025, Keros Therapeutics adopted a "poison pill" defense against hostile takeovers and initiated a review of strategic alternatives. In June 2025, Bank of America Securities downgraded KROS, and a major shareholder criticized the board's capital allocation decisions. In February 2026, Keros Therapeutics shares traded down modestly due to broad-based pressure in the biotech sector.

As a clinical-stage biopharmaceutical company, Keros Therapeutics does not experience significant demand seasonality in the traditional sense. Demand for its pipeline candidates is driven by clinical trial progress, regulatory milestones, and unmet medical needs.

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel protein therapeutics for disorders linked to dysfunctional TGF-β signaling. Their pipeline includes KER-050 (elritercept) for cytopenias, KER-012 (cibotercept) in Phase II trials for PAH and cardiovascular disorders, and KER-065 in Phase I trials for obesity and neuromuscular diseases like DMD.

Keros Therapeutics is headquartered in Lexington, Massachusetts, United States. Clinical trials for KER-050 are being conducted across North America and Europe.

Keros Therapeutics' brand reputation has been mixed, with a major setback in December 2024 due to safety concerns in a clinical trial. The company's proactive defense against hostile takeovers in April 2025 was met with positive sentiment. However, a major analyst downgraded the stock in June 2025, and a prominent shareholder expressed dissatisfaction with capital allocation, indicating challenges in investor confidence and corporate governance.

Keros Therapeutics has significant institutional ownership, with 273 institutional owners and shareholders holding approximately 86.8% of the company's shares, primarily from the United States. Major institutional owners include ADAR1 Capital Management, LLC, BlackRock, Inc., Madison Avenue Partners, LP, and Vanguard Group Inc.